FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4318948364> ?p ?o ?g. }

• W4318948364 endingPage "356" @default.
• W4318948364 startingPage "347" @default.
• W4318948364 abstract "The benefit of pharmacogenetic testing before starting drug therapy has been well documented for several single gene-drug combinations. However, the clinical utility of a pre-emptive genotyping strategy using a pharmacogenetic panel has not been rigorously assessed.We conducted an open-label, multicentre, controlled, cluster-randomised, crossover implementation study of a 12-gene pharmacogenetic panel in 18 hospitals, nine community health centres, and 28 community pharmacies in seven European countries (Austria, Greece, Italy, the Netherlands, Slovenia, Spain, and the UK). Patients aged 18 years or older receiving a first prescription for a drug clinically recommended in the guidelines of the Dutch Pharmacogenetics Working Group (ie, the index drug) as part of routine care were eligible for inclusion. Exclusion criteria included previous genetic testing for a gene relevant to the index drug, a planned duration of treatment of less than 7 consecutive days, and severe renal or liver insufficiency. All patients gave written informed consent before taking part in the study. Participants were genotyped for 50 germline variants in 12 genes, and those with an actionable variant (ie, a drug-gene interaction test result for which the Dutch Pharmacogenetics Working Group [DPWG] recommended a change to standard-of-care drug treatment) were treated according to DPWG recommendations. Patients in the control group received standard treatment. To prepare clinicians for pre-emptive pharmacogenetic testing, local teams were educated during a site-initiation visit and online educational material was made available. The primary outcome was the occurrence of clinically relevant adverse drug reactions within the 12-week follow-up period. Analyses were irrespective of patient adherence to the DPWG guidelines. The primary analysis was done using a gatekeeping analysis, in which outcomes in people with an actionable drug-gene interaction in the study group versus the control group were compared, and only if the difference was statistically significant was an analysis done that included all of the patients in the study. Outcomes were compared between the study and control groups, both for patients with an actionable drug-gene interaction test result (ie, a result for which the DPWG recommended a change to standard-of-care drug treatment) and for all patients who received at least one dose of index drug. The safety analysis included all participants who received at least one dose of a study drug. This study is registered with ClinicalTrials.gov, NCT03093818 and is closed to new participants.Between March 7, 2017, and June 30, 2020, 41 696 patients were assessed for eligibility and 6944 (51·4 % female, 48·6% male; 97·7% self-reported European, Mediterranean, or Middle Eastern ethnicity) were enrolled and assigned to receive genotype-guided drug treatment (n=3342) or standard care (n=3602). 99 patients (52 [1·6%] of the study group and 47 [1·3%] of the control group) withdrew consent after group assignment. 652 participants (367 [11·0%] in the study group and 285 [7·9%] in the control group) were lost to follow-up. In patients with an actionable test result for the index drug (n=1558), a clinically relevant adverse drug reaction occurred in 152 (21·0%) of 725 patients in the study group and 231 (27·7%) of 833 patients in the control group (odds ratio [OR] 0·70 [95% CI 0·54-0·91]; p=0·0075), whereas for all patients, the incidence was 628 (21·5%) of 2923 patients in the study group and 934 (28·6%) of 3270 patients in the control group (OR 0·70 [95% CI 0·61-0·79]; p <0·0001).Genotype-guided treatment using a 12-gene pharmacogenetic panel significantly reduced the incidence of clinically relevant adverse drug reactions and was feasible across diverse European health-care system organisations and settings. Large-scale implementation could help to make drug therapy increasingly safe.European Union Horizon 2020." @default.
• W4318948364 created "2023-02-03" @default.
• W4318948364 creator A5000150545 @default.
• W4318948364 creator A5001499741 @default.
• W4318948364 creator A5002915510 @default.
• W4318948364 creator A5003155980 @default.
• W4318948364 creator A5004720639 @default.
• W4318948364 creator A5005313310 @default.
• W4318948364 creator A5006074058 @default.
• W4318948364 creator A5006391058 @default.
• W4318948364 creator A5006483134 @default.
• W4318948364 creator A5006624841 @default.
• W4318948364 creator A5006705263 @default.
• W4318948364 creator A5006847944 @default.
• W4318948364 creator A5007032964 @default.
• W4318948364 creator A5007189070 @default.
• W4318948364 creator A5007438536 @default.
• W4318948364 creator A5007736975 @default.
• W4318948364 creator A5008025189 @default.
• W4318948364 creator A5008054295 @default.
• W4318948364 creator A5008349219 @default.
• W4318948364 creator A5008704343 @default.
• W4318948364 creator A5008719374 @default.
• W4318948364 creator A5009594336 @default.
• W4318948364 creator A5009664323 @default.
• W4318948364 creator A5009934087 @default.
• W4318948364 creator A5009976972 @default.
• W4318948364 creator A5010418794 @default.
• W4318948364 creator A5010459983 @default.
• W4318948364 creator A5010504320 @default.
• W4318948364 creator A5011417365 @default.
• W4318948364 creator A5011603252 @default.
• W4318948364 creator A5011914130 @default.
• W4318948364 creator A5011938990 @default.
• W4318948364 creator A5012456972 @default.
• W4318948364 creator A5012638237 @default.
• W4318948364 creator A5012663065 @default.
• W4318948364 creator A5013161841 @default.
• W4318948364 creator A5013843450 @default.
• W4318948364 creator A5014475207 @default.
• W4318948364 creator A5014495295 @default.
• W4318948364 creator A5014888987 @default.
• W4318948364 creator A5015284751 @default.
• W4318948364 creator A5015305852 @default.
• W4318948364 creator A5015310339 @default.
• W4318948364 creator A5015439101 @default.
• W4318948364 creator A5015445323 @default.
• W4318948364 creator A5015526160 @default.
• W4318948364 creator A5016183929 @default.
• W4318948364 creator A5016556908 @default.
• W4318948364 creator A5016796399 @default.
• W4318948364 creator A5017886278 @default.
• W4318948364 creator A5018127159 @default.
• W4318948364 creator A5018168610 @default.
• W4318948364 creator A5018725278 @default.
• W4318948364 creator A5019106572 @default.
• W4318948364 creator A5019268165 @default.
• W4318948364 creator A5019371897 @default.
• W4318948364 creator A5019395403 @default.
• W4318948364 creator A5020002430 @default.
• W4318948364 creator A5020419436 @default.
• W4318948364 creator A5021554334 @default.
• W4318948364 creator A5021809630 @default.
• W4318948364 creator A5021976049 @default.
• W4318948364 creator A5022076796 @default.
• W4318948364 creator A5022427683 @default.
• W4318948364 creator A5022429204 @default.
• W4318948364 creator A5022610940 @default.
• W4318948364 creator A5023354304 @default.
• W4318948364 creator A5023493843 @default.
• W4318948364 creator A5023576846 @default.
• W4318948364 creator A5024531303 @default.
• W4318948364 creator A5025869866 @default.
• W4318948364 creator A5026258602 @default.
• W4318948364 creator A5026565501 @default.
• W4318948364 creator A5027943285 @default.
• W4318948364 creator A5028538410 @default.
• W4318948364 creator A5028791127 @default.
• W4318948364 creator A5030227550 @default.
• W4318948364 creator A5030261153 @default.
• W4318948364 creator A5030272382 @default.
• W4318948364 creator A5030766061 @default.
• W4318948364 creator A5030905698 @default.
• W4318948364 creator A5031034390 @default.
• W4318948364 creator A5031363850 @default.
• W4318948364 creator A5031750812 @default.
• W4318948364 creator A5031823460 @default.
• W4318948364 creator A5032077534 @default.
• W4318948364 creator A5032600927 @default.
• W4318948364 creator A5032698942 @default.
• W4318948364 creator A5033137752 @default.
• W4318948364 creator A5033279968 @default.
• W4318948364 creator A5033703943 @default.
• W4318948364 creator A5034153862 @default.
• W4318948364 creator A5034802700 @default.
• W4318948364 creator A5036052498 @default.
• W4318948364 creator A5036108679 @default.
• W4318948364 creator A5036352166 @default.

• next